{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:20:12Z","timestamp":1787242812409,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01834-2","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:29:15Z","timestamp":1786192155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-8718","authenticated-orcid":false,"given":"Serena","family":"Pillozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giommoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lavacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"1834_CR1","doi-asserted-by":"publisher","unstructured":"Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW, Besselink MG. Pancreatic cancer. Lancet. 2025;405(10485):1182\u20131202. doi: 10.1016\/S0140-6736(25)00261-2. Erratum in: Lancet. 2025;405(10491):1742. https:\/\/doi.org\/10.1016\/S0140-6736(25)00992-4. PMID: 40187844.","DOI":"10.1016\/S0140-6736(25)00992-4"},{"issue":"5","key":"1834_CR2","first-page":"e261048","volume":"9","author":"J Cho","year":"2026","unstructured":"Cho J, Lee T, Kim H, et al. Association of mutation landscapes and clinical traits in advanced pancreatic ductal adenocarcinoma: a national cohort analysis. JAMA Netw Open. 2026;9(5):e261048.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1834_CR3","first-page":"245","volume":"10","author":"X Wang","year":"2025","unstructured":"Wang X, Huang L, Guo Z, Wang F, Fu L. KRAS targeted therapies in cancer: novel approaches and overcoming the undruggable historical paradigm. Signal Transduct Target Ther. 2025;10(4):245\u201361.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1834_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ccell.2026.01.001","volume":"44","author":"JM Riedl","year":"2026","unstructured":"Riedl JM, Matsubara H, McNeil R, Patel PS, Fece de la Cruz F, Gulhan DC, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026;44(3):412\u201331.","journal-title":"Cancer Cell"},{"issue":"2","key":"1834_CR5","first-page":"114","volume":"32","author":"L Rossi","year":"2026","unstructured":"Rossi L, Marini M, Conroy T, et al. Pancreatic cancer in 2026: Have we finally found a path through the desmoplastic stroma? World J Gastroenterol. 2026;32(2):114\u201329.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1834_CR6","doi-asserted-by":"publisher","first-page":"e2453588","DOI":"10.1001\/jamanetworkopen.2024.53588","volume":"8","author":"C Norton","year":"2025","unstructured":"Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou V. KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Netw Open. 2025;8(1):e2453588. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.53588. PMID: 39777438; PMCID: PMC11707629.","journal-title":"JAMA Netw Open"},{"key":"1834_CR7","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"BM Wolpin","year":"2026","unstructured":"Wolpin BM, Park W, Garrido-Laguna I, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (RASolute 302). N Engl J Med. 2026;394:1790\u2013802.","journal-title":"N Engl J Med"},{"issue":"3","key":"1834_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ccell.2026.01.001","volume":"44","author":"JM Riedl","year":"2026","unstructured":"Riedl JM, Matsubara H, McNeil R, Patel PS, Fece de la Cruz F, Gulhan DC, et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell. 2026;44(3):412\u201331.","journal-title":"Cancer Cell"},{"issue":"16_suppl","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2026.44.16_suppl.3007","volume":"44","author":"Y Yu","year":"2026","unstructured":"Yu Y, Liu T, Xue J, et al. Phase I\/IIa study of DN022150, a novel selective noncovalent small molecule KRAS G12D inhibitor in patients with advanced KRAS G12D-mutant solid tumors. J Clin Oncol. 2026;44(16_suppl):3007. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.3007.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1200\/JCO.2026.44.16_suppl.4190","volume":"44","author":"X Yu","year":"2026","unstructured":"Yu X, et al. HRS-4642 combined with adebrelimab in previously treated patients with metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2026;44(16_suppl):4190. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.4190.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1834_CR11","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1200\/JCO.2026.44.16_suppl.4191","volume":"44","author":"J Xu","year":"2026","unstructured":"Xu J, et al. SHR-A2102, a Nectin-4 targeted antibody-drug conjugate, combined with HRS-4642 in previously treated pancreatic ductal adenocarcinoma harboring KRAS G12D mutation. J Clin Oncol. 2026;44(16_suppl):4191. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.4191.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1834_CR12","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/JCO.2026.44.16_suppl.3078","volume":"44","author":"A Zivi","year":"2026","unstructured":"Zivi A, Hong DS, Patel MR, et al. Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) in combination with adagrasib in KRAS G12C mutated advanced solid tumors: Preliminary results from the FIT-001 phase 1 first-in-human trial. J Clin Oncol. 2026;44(16_suppl):3078. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.3078.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01834-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01834-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01834-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:29:16Z","timestamp":1786192156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01834-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01834-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"<b>Ethics approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DR: speakers\u2019 Bureau: Amgen, Pierre Fabre, Bayer, Takeda, MSD, Merck; travel: Merck. EG: Abbvie, Servier, Gentili; travel: Ipsen. DL: advisory: Daiichi Sankyo, MSD, Amgen, Servier; travel: Servier, Merck, Amgen, Pfizer. LA: payment or honoraria for lectures and presentation: ASTRA ZENECA, ROCHE, ASTELLAS, NOVARTIS, MSD, BMS, IPSEN, MERK SERONO, AMGEN, BAYER; support for attending meeting and\/or travel grant: ASTRA ZENECA, NOVARTIS, IPSEN, MERK SERONO, AMGEN, SERVIER; advisory Board: Abbott, Pharmacosmos, BMS. GP, AG, SP and MB have no competing interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"53"}}